Results 61 to 70 of about 7,237,819 (287)

Unlocking the potential of cell‐permeable nanobodies for intracellular applications

FEBS Letters, EarlyView.
This review outlines current strategies for delivery of nanobodies into cells and highlights recent examples of functional applications. By addressing and manipulating intracellular targets, these molecules hold great potential for treating cancer, respiratory diseases and neurological disorders, making this a vibrant area of research in the biomedical
Mariona Gené‐Verdés, Luise Franz, Christian P.R. Hackenberger   +2 more
wiley   +1 more source

Immunogenic Cell Death Role in Urothelial Cancer Therapy

Current Oncology, 2022
Purpose: Bladder cancer is the 13th most common cause of cancer death with the highest lifetime cost for treatment of all cancers. This scoping review clarifies the available evidence on the role of a novel therapeutic approach called immunogenic cell ...
Reza Yadollahvandmiandoab, Mehrsa Jalalizadeh, Keini Buosi, Herney Andrés Garcia-Perdomo, Leonardo Oliveira Reis   +4 more
doaj   +1 more source

Immunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation

, 2010
Immunogenic profile of certain cancer cell death mechanisms has been transmuted by research published over a period of last few years and this change has been so drastic that a new (sub)class of apoptotic cancer cell death, redefined as ‘immunogenic ...
Golab, Jakub, Golab, J, Vandenabeele, Peter, Garg, Abhishek, Agostinis, Patrizia, Nowis, D, Garg, AD, Krysko, Dmitri, Agostinis, P, Nowis, Dominika, Krysko, Dmitri V., Dominika Nowis, Patrizia Agostinis, Jakub Golab, Dmitri V. Krysko, Abhishek D. Garg, Peter Vandenabeele   +16 more
core   +1 more source

Induction of Immunogenic Tumor Cell Death by Attenuated Oncolytic Measles Virus [PDF]

, 2015
International audienceAntitumor virotherapy is a developing approach to treat cancer with oncolytic viruses, namely replicative viruses that exclusively or preferentially infect and kill tumor cells. Attenuated strains of Measles Virus (MV) are now being
Delaunay, Tiphaine, Tangy, Frédéric, Boisgerault, Nicolas, Achard, Carole, Grégoire, Marc, Fonteneau, Jean-François   +5 more
core   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Crizotinib-induced immunogenic cell death in non-small cell lung cancer

Nature Communications, 2019
Certain chemotherapeutic agents can exert their anticancer effect through indirect immune-dependent mechanism. Here, the authors screen a library of tyrosine kinase inhibitors and show that crizotinib is an effective stimulator of immunogenic cell death ...
Peng Liu, Liwei Zhao, Jonathan Pol, Sarah Levesque, Adriana Petrazzuolo, Christina Pfirschke, Camilla Engblom, Steffen Rickelt, Takahiro Yamazaki, Kristina Iribarren, Laura Senovilla, Lucillia Bezu, Erika Vacchelli, Valentina Sica, Andréa Melis, Tiffany Martin, Lin Xia, Heng Yang, Qingqing Li, Jinfeng Chen, Sylvère Durand, Fanny Aprahamian, Deborah Lefevre, Sophie Broutin, Angelo Paci, Amaury Bongers, Veronique Minard-Colin, Eric Tartour, Laurence Zitvogel, Lionel Apetoh, Yuting Ma, Mikael J. Pittet, Oliver Kepp, Guido Kroemer   +33 more
doaj   +1 more source

Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology

OncoImmunology, 2020
The term ‘immunogenic cell death’ (ICD) denotes an immunologically unique type of regulated cell death that enables, rather than suppresses, T cell-driven immune responses that are specific for antigens derived from the dying cells. The ability of ICD to
Isaure Vanmeerbeek, Jenny Sprooten, Dirk De Ruysscher, Sabine Tejpar, Peter Vandenberghe, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi, Abhishek D. Garg   +10 more
doaj   +1 more source

Immunogenic cell death [PDF]

, 2018
According to the danger model, the immune system is activated by endogenous molecules known as danger-associated molecular patterns (DAMP) that are externalized from the interior of a dying cell to the cell surface or released into the extracellular ...
Šímová, Michaela
core  

Immunogenic cell death inducers as anticancer agents

Oncotarget, 2014
It has been widely thought that the occasional success of anticancer chemotherapies is mediated by direct, efficient cytostatic or (better) cytotoxic effects of the antineoplastic agent on tumor cells. Nonetheless, there is accumulating evidence for the hypothesis that long-term clinical success (which is measured in years and decades rather than weeks
Oliver, Kepp, Laura, Senovilla, Guido, Kroemer   +2 more
openaire   +2 more sources